Ponatinib vs Imatinib for Newly Diagnosed Patients With Ph-Positive ALL
Posted: 02/22/2023 | By: Chase Doyle

PhALLCON, the first randomized study comparing tyrosine kinase inhibitors in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), evaluated ponatinib vs imatinib in combination with reduced-intensity chemotherapy. Results were presented by Jabbour et al during the February ASCO Plenary Series session (Abstract 398868).

Question 1 of 5

What is the primary endpoint of the phase III PhALLCON study?

Choose 1